Biomarker-guided changes to anti-rejection medicines after kidney transplant
Treatments studied
Part of Kidney & urinary clinical trials.
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can understand the study and sign informed consent
- You received (within 14 days) or are planning an ABO-compatible kidney transplant (including A2 to B)
- Before the transplant, your immune “matching” tests are negative (panel reactive antibody ≤ 60% and virtual cross-match or donor-specific antibody is negative)
- You must be on three anti-rejection medicines together: tacrolimus + mycophenolate + prednisone at set minimum doses
- For women who could become pregnant: you must have a negative pregnancy test and use highly effective birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a blood test that may help monitor kidney transplant health by detecting signs of rejection earlier. It aims to see if using this blood test can lead to better long-term outcomes for transplant recipients.
This study tests a new way to monitor harmful antibodies after a kidney transplant. It may help prevent transplant rejection over time.
This study tests whether continuing certain anti-rejection medicines while on dialysis can help lower the risk of your immune system becoming too sensitive to a future kidney transplant. It might help you stay eligible for another transplant later.
This study tests a new combination of drugs (an antibody called CD38 mAb plus azathioprine) to treat a type of chronic rejection that can happen months or years after a kidney transplant. The goal is to see if it can help stabilize or improve kidney function and prevent further damage.
This trial uses DNA testing and gene expression profiling to see if kidney transplant recipients can safely switch to a belatacept-only immunosuppression regimen. The goal is to simplify your anti-rejection drugs while keeping your kidney healthy.
This trial tests whether belatacept can help prevent damage in kidney transplant recipients who develop new antibodies against their donor kidney. It is for people whose kidney function is still stable, which may allow treatment to slow or stop antibody-related injury.
Hear when a new Kidney Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.